COCs containing dienogest and 30 µg ethinylestradiol may carry a higher VTE risk compared to corresponding preparations with levonorgestrel: A meta-analysis of four large cohort studies

Jürgen Dinger

doi:10.15761/fwh.1000175

COCs containing dienogest and 30 µg ethinylestradiol may carry a higher VTE risk compared to corresponding preparations with levonorgestrel: A meta-analysis of four large cohort studies

Jürgen Dinger

In: Frontiers in Women’s Health · 2020 · vol. 5(1) · doi:10.15761/fwh.1000175 · W3033220769

article OA: diamond CC0 ⤵ 2 in-corpus citations

📄 Open PDF View on OpenAlex View at publisher

Abstract

The European Medicines Agency requested a meta-analysis of four large, multi-national cohort studies on hormonal contraceptives to clarify whether dienogest/ethinylestradiol-containing combined oral contraceptives (DNG/EE) carry a different risk of venous thromboembolic events (VTE) compared to levonorgestrel/ethinylestradiol-containing preparations (LNG/EE). The primary objective of the meta-analysis was to assess VTE risk in a study population that is representative for the actual users of the individual preparations.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Impact of estrogen type on cardiovascular safety of combined oral contraceptives 2016

Cited by (2)

References (25)

Impact of estrogen type on cardiovascular safety of combined oral contraceptives via openalex
doi:10.1126/science.7618077 via openalex
doi:10.1136/bmj.b2890 via openalex
doi:10.1093/oxfordjournals.aje.a117324 via openalex
doi:10.1136/bmj.d2151 via openalex
doi:10.1783/147118908786000596 via openalex
doi:10.1016/j.jemermed.2013.03.012 via openalex
doi:10.1503/cmaj.120677 via openalex
doi:10.1093/oxfordjournals.aje.a117326 via openalex
doi:10.1002/tera.1420460110 via openalex
doi:10.1783/147118908784734873 via openalex
W2184707592 via openalex
doi:10.1001/archinternmed.2008.589 via openalex
W4379510236 via openalex
doi:10.1177/003591576505800503 via openalex
doi:10.1016/j.contraception.2016.01.012 via openalex
doi:10.1016/j.contraception.2014.01.023 via openalex
doi:10.1016/s0140-6736(00)04645-6 via openalex
doi:10.1093/ije/17.4.955 via openalex
doi:10.1093/oxfordjournals.aje.a115939 via openalex
doi:10.2307/2531021 via openalex
doi:10.1097/aog.0b013e3182a5ec6b via openalex
doi:10.1016/s0895-4356(96)00360-5 via openalex
doi:10.1093/oxfordjournals.aje.a010135 via openalex
doi:10.1080/02664760802366775 via openalex

Cited by (2)

Source provenance

openalex: last seen: 2026-05-13T18:27:55.367740+00:00

License: CC0 · commercial use OK

[1] Impact of estrogen type on cardiovascular safety of combined oral contraceptives 2016